Switzerland authorizes remdesivir for use against COVID-19

first_imgFollowing a swift review this week, Swissmedic, the national agency for therapeutic products, said it would allow the temporary distribution of the drug, which was originally intended as a treatment for Ebola. US studies show that the anti-viral drug remdesivir can reduce the duration of hospital stays for those suffering from the novel coronavirus. Switzerland announced Thursday that COVID-19 patients beyond those on clinical trials could be given remdesivir, the first drug shown to be relatively effective in treating the new coronavirus. The product will be made available to patients outside approved clinical trials and the approved compassionate use programme, pending a decision on full authorization of the drug. “Products containing the active substance remdesivir and marketed under the brand name Veklury may be used in Swiss hospitals, without authorization, for the treatment of COVID-19 patients,” the statement said.center_img At least two major US studies have shown that the anti-viral drug can reduce the duration of hospital stays for those suffering from the novel coronavirus. “With immediate effect, remdesivir can be used more widely in Switzerland for the treatment of COVID-19 patients,” the government said in a statement. Clinicians will monitor any adverse reactions to the drug to ensure patient safety, the government said. (AFP)last_img